ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Alloantigens"

  • 2016 American Transplant Congress

    Alemtuzumab Is Safe and Effective Induction Therapy in Highly Sensitized (HS) Pediatric Patients Undergoing Transplantation.

    I. Kim,1 J. Choi,1 A. Vo,1 A. Kang,1 M. Toyoda,1 J. Mirocha,2 E. Kamil,1 S. Louie,1 O. Galera,1 S. Jordan,1 D. Puliyanda.1

    1Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; 2Biostatistics Core, Cedars-Sinai Medical Center, Los Angeles, CA.

    Introduction: Studies show that alemtuzumab, a potent lymphocyte-depleting agent, is well-tolerated in pediatric renal transplantation. We report on the use of alemtuzumab induction in HS…
  • 2016 American Transplant Congress

    The Distance Between Us: The Landscape of Recipient-Specific Loss-of-Function in Solid Organ Transplantation and Association with Rejection-Free Graft Survival.

    B. Cole,1,2,5 J. van Setten,3,5 B. Keating.1,4,5

    1Department of Surgery, The Penn Transplant Institute, Philadelphia, PA; 2Center for Clinical Epidemiology and Biostatistics, The Institute for Biomedical Informatics, Philadelphia, PA; 3Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands; 4Department of Surgery, Division of Transplant, the Children's Hospital of Philadelphia, Philadelphia, PA; 5The Omics Working Group, iGeneTRAiN Consortium, Philadelphia, PA.

    Purpose: This study aims to comprehensively identify genes that are inactivated in both copies in transplant recipients but not in their respective donors, uncovering a…
  • 2016 American Transplant Congress

    Tracking of Endogenous Graft-Reactive Tregs Reveals Their Peripheral Enrichment During Transplantation Tolerance.

    J. Young,1 J. Chen,1 M. Miller,1 D. Yin,1 J. Moon,2 M.-L. Alegre,1 A. Chong.1

    1Surgery and Medicine, University of Chicago, Chicago, IL; 2Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA.

    Purpose: Our goal for this study was to determine the relative fates of endogenous Foxp3- conventional (Tconv) and Foxp3+ regulatory T cells (Tregs) specific for…
  • 2016 American Transplant Congress

    Role of Regulatory T Cells in Induction of Tolerance in Mouse Vascularized Osteomyocutaneous Allotransplantation Under Combined Costimulation Blockade.

    M. Anggelia,1 H.-Y. Cheng,1 Y.-L. Wang,1 W.-Y. Chuang,1 C.-H. Lin,1 G. Brandacher,2 F.-C. Wei,1 C.-H. Lin.1

    1Center for Vascularized Composite Allotransplantation, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan; 2Department of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation (VCA) Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD.

    Background: The role of regulatory T cells (Tregs) in allograft tolerance has been studied using various transplant models, but the mechanism in vascularized composite allotransplantation…
  • 2016 American Transplant Congress

    Profiling Metabolic Differences Between Graft- vs. Pathogen-Elicited CD8+ T Cell Responses.

    A. Karp, M. Wagener, J. Robertson, M. Ford.

    Emory University, Atlanta.

    The challenge of immune modulation in transplantation is to inhibit pathologic alloreactivity while minimizing off-target toxicities and preserving protective immunity. Data have emerged demonstrating the…
  • 2016 American Transplant Congress

    Aquaporin 4 Blockade Is a Novel Strategy to Prevent T Cell Activation and Effector Functions.

    K. Ayasoufi,1 N. Kohei,1 G. Farr,2 P. McGuirk,2 M. Pelletier,2 R. Fairchild,1 A. Valujskikh.1

    1Cleveland Clinic, Cleveland; 2Aeromics LLC, Cleveland.

    Aquaporin 4 (AQP4) belongs to the family of integral transmembrane proteins highly permeable to water. We have previously reported that blocking AQP4 with small molecule…
  • 2015 American Transplant Congress

    Detection of Donor Specific HLA-Ab (DSA) Against Native HLA Molecules Expressed On Donor Cell Surface to Eliminate False Positive DSA in Luminex Single Antigen Beads (LMX-SAB)

    G. Chen, L. Lin, D. Tyan.

    Pathology, Stanford University, Palo Alto, CA.

    Introduction:The LMX-SAB has been extensively used for DSA virtual crossmatch (VXM) to predict actual crossmatch (AXM). The extreme pH and harsh chemical reaction conditions used…
  • 2015 American Transplant Congress

    Bortezomib Treatment in Antibody Mediated Rejection After Kidney Transplantation

    J. Lee,1 J. Lee,1 B. Kim,2 Y. Park,3 M. Ju,1 M. Kim,1 S. Kim,1 Y. Kim,1 K. Huh.1

    1Department of Transplantation Surgery, Yonsei University Health System, Seoul, Republic of Korea; 2Department of Internal Medicine, Yonsei University Health System, Seoul, Republic of Korea; 3Department of Laboratory Medicine, Yonsei University Health System, Seoul, Republic of Korea.

    BackgroundSeveral studies demonstrated bortezomib therapy for antibody-mediated rejection (AMR) in renal transplants. However, the treatment efficacy according to target antigen or occurrence time of AMR…
  • 2015 American Transplant Congress

    The Effect of Compatibility of ABO Blood Type Antigens on Graft Survival of Intestinal Transplants

    J. Cai,1 A. Qing,2 G. Wu,3 M. Everly,1 P. Terasaki.1

    1Terasaki Foundation Lab, Los Angeles; 2Lincoln High School, Stockton; 3The 4th Military Medical University, Xi-An, China.

    Due to the introduction of new immunosuppressive agents and development of pre- and post-transplant patient management, ABO blood group incompatibility is no longer considered an…
  • 2015 American Transplant Congress

    Immunologic, Proangiogenic and Neurogenic Assessment of Allogenic Epineurium of the Human Peripheral Nerve for Potential Application in Prevention of Neuroma Formation

    A. Klimczak,1 K. Futoma,2 A. Jundzill,3 D. Patrzalek,4 M. Siemionow.5

    1Clinical Immunology Department, Institute of Immunology and Experimental Therapy PAS, Wroclaw, Poland; 2Wroclaw Research Centre EIT+, Wroclaw, Poland; 3Regenerative Medicine Tissue Engineering Department, Nicolaus Copernicus University Collegium Medicum, Bydgoszcz, Poland; 4Department of Surgery, 4th Military Clinical Hospital, Wroclaw, Poland; 5Department of Orthopaedics, The University of Illinois at Chicago, Chicago, IL.

    Purpose: Transplantation of epineural sheath may support nerve regeneration after traumatic nerve injuries. Unsolved problem after nerve injury is painful neuroma formation. Natural biologic material,…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences